BC-DXI-843

2421117-98-6

546.66

DMSO : 250 mg/mL (457.32 mM; Need ultrasonic)

Others

BC-DXI-843 is a potent and specific AIMP2-DX2 inhibitor with an IC₅₀ of 0.92 uM, more than 100-fold selectivity over AIMP2 (IC₅₀ >100 uM) in a luciferase assay. BC-DXI-843 acts as a promising lead targeting AIMP2-DX2 in lung cancer^[1]. IC50 & Target: IC50: 0.92 uM (AIMP2-DX2), IC50: >100 uM (AIMP2)^[1] In Vitro: BC-DXI-843 (0.0316-31.6 uM; 72 hours) suppresses cancer cell proliferation in a DX2-dependent manner. The EC₅₀ in A549 cells is 1.20 uM, which is similar to the IC₅₀ for inhibition of DX2. However, no inhibition of WI-26 cells is observed, suggesting that BC-DXI-843 specifically reduces the viability of cancer cells^[1]. In Vivo: BC-DXI-843 (50 mg/kg; intraperitoneally administered; every other day for 15 days) demonstrates in vivo efficacy in a tumor xenograft mouse model (H460 cells)^[1].